Is Cortical Bone Hip? What determines Cortical Bone Properties?

Bone

Volumn 41, Issue 1 SUPPL., 2007, Pages S3-

  Epstein, Sol ^a,b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Doylestown Hospital   (United States)

Author keywords

Bone marker; Cortical; Osteocyte; Periosteal; Trabecular

Indexed keywords

ALENDRONIC ACID; ANABOLIC AGENT; ANDROGEN RECEPTOR; BIOCHEMICAL MARKER; BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; DENOSUMAB; ESTROGEN; ESTROGEN RECEPTOR; IBANDRONIC ACID; MONOCLONAL ANTIBODY; OSTEOCLAST DIFFERENTIATION FACTOR; PARATHYROID HORMONE[1-34]; RISEDRONIC ACID; STRONTIUM RANELATE; TESTOSTERONE;

APOPTOSIS; ARTICLE; BONE DENSITY; BONE REMODELING; BONE STRENGTH; BONE STRUCTURE; BONE TURNOVER; CORTICAL BONE; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; FRACTURE; HIP; HIP FRACTURE; HUMAN; NONHUMAN; OSTEOCYTE; OSTEOLYSIS; OSTEOPOROSIS; POROSITY; SPINE FRACTURE; TRABECULAR BONE;

EID: 34250305557     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2007.03.006     Document Type: Article

References (36)

1. Manolagas S.C. Choreography from the tomb: an emerging role of dying osteocytes in the purposeful, and perhaps not so purposeful, targeting of bone remodeling. BoneKEY Osteovision 3 (2006) 5-14
2. Wang L., Wang Y., Han Y., et al. In situ measurement of solute transport in the bone lacunar-canalicular system. Proc. Natl. Acad. Sci. U. S. A. 33 (2005) 11911-11916
3. Bonewald L. Mechanosensation and transduction in osteocytes. BoneKEY Osteovision 10 (2006) 7-15
4. Aarden E.M., Nijweide P.J., Van der Plas A., et al. Adhesive properties of isolated chick osteocytes in vitro. Bone 18 (1996) 305-313
5. You L.D., Weinbaum S., Cowin S.C., et al. Ultrastructure of the osteocyte process and its pericelluar matrix. Anat. Rec., A Discov. Mol. Cell Evol. Biol. 278 (2004) 505-513
6. Frank J.D., Ryan M., Kalscheur V.L., Ruaux-Mason C.P., Hozak R.R., and Muir P. Aging and accumulation of microdamage in canine bone. Bone 30 (2002) 201-206
7. Qiu S., Rao D.S., Palnitkar S., and Parfitt A.M. Reduced iliac function cancellous osteocyte density in patients with osteoporotic vertebral fractures. J. Bone Miner. Res. 18 (2003) 1657-1663
8. Vashishth D., Verborgt O., Divine G., Schaffler M.B., and Fyhrie D.P. Decline in osteocyte lacunar density in human cortical bone is associated with accumulation of microcracks with age. Bone 26 (2000) 375-380
9. Allen M.R., Hock J.M., and Burr D.B. Periosteum: biology, regulation, and response to osteoporosis therapies. Bone 35 (2004) 1003-1012
10. Bliziotes M., Sibonga J.D., Turner R.T., and Orwoll E. Periosteal remodelling at the femoral neck in nonhuman primates. J. Bone Miner. Res. (2006) 1060-1067
11. Szulc P., Seeman R., Duboeuf F., Sornay-Rendu E., and Delmas P.D. Bone fragility: failure of periosteal apposition to compensate for increased endocortical resorption in postmenopausal women. J. Bone Miner. Res. 12 (2006) 1863-1865
12. Bousson V., Bergot C., Meunier A., et al. CT of the middiaphyseal femur: cortical bone mineral density and relation to porosity. Radiology 217 (2000) 179-187
13. Bell K.L., Loveridge N., Jordan G.R., Power J., Constant C.R., and Reeve J. Super-osteons (remodeling clusters) in the cortex of the femoral shaft: Influence of age and gender. Bone 27 (2000) 297-304
14. Greenspan S.L., Beck T.J., Resnick N.M., Bhattacharya R., and Parker R.A. Effect of hormone replacement, alendronate, or combination therapy on hip structural geometry: a 3-year, double-blind, placebo-controlled clinical trial. J. Bone Miner. Res. 20 (2005) 1525-1532
15. Roschger P., Rinnerthaler S., Yates J., Rodan G.A., Fratzl P., and Klaushofer K. Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women. Bone 29 (2001) 185-191
16. Vandenput L., Swinnen J.V., Boonen S., et al. Role of the androgen receptor in skeletal homeostasis: and androgen-resistant testicular feminized male mouse model. J. Bone Miner. Res. 19 (2004) 1462-1470
17. Venken K., De Gendt K., Boonen S., et al. Relative impact of androgen and estrogen receptor activation in the effects of androgens on trabecular and cortical bone in growing male mice: a study in the androgen receptor knockout mouse model. J. Bone Miner. Res. 21 (2006) 576-585
18. Kawano H., Takashi S., Takashi Y., et al. Suppressive function of androgen receptor in bone resorption. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 9416-9421
19. Vanderschueren D., Vandenput L., Boonen S., Lindberg M.K., Bouillon R., and Ohlsson C. Androgens and bone. Endocr. Rev. 25 (2004) 389-425
20. /-mice. J. Clin. Invest. 104 (1999) 895-901
21. Khosla S. Sex hormone binding globulin: inhibitor or facilitator (or both) of sex steroid action?. J. Clin. Endocrinol. Metab. 12 (2006) 4764-4766
22. Venken K., Moverare-Skrtic S., and Kopchick J.J. Impact of androgens, growth hormones, and igf-I on bone and muscle in male mice during puberty. J. Bone Miner. Res. 1 (2007) 72-82
23. Khosla J., Melton J., Achenbach S., Oberg A., and Riggs B. Hormonal and biochemical determinants of trabecular microstructure at the ultradistal radius in women and men. J. Clin. Endocrinol. Metab. 91 (2006) 885-891
24. Riggs K., and Melton L.J. Bone turnover matters: the raloxifene treatment paradox of dramatic decreases in vertebral fracture without commensurate increases in bone density. J. Bone Miner. Res. 17 (2002) 11-14
25. Wachter N.J., Krischak G.D., Mentzel M., et al. Correlation of bone mineral density with strength and microstructural parameters of cortical bone in vivo. Bone 31 (2002) 90-95
26. Bauer D.C., Black D.M., Garnero P., et al. Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J. Bone Miner. Res. 19 (2004) 1250-1258
27. Eastell R., Barton I., Hannon R.A., Chines A., Garnero P., and Delmas P.D. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J. Bone Miner. Res. 18 (2003) 1051-1056
28. Eswaran SK, Bevill G, Allen MR, Burr DB, Keaveny TM. Effect of risedronate on cortical and trabecular load sharing characteristics of the canine vertebral body. Presented at the American Society of Bone and Mineral 2006. Presented at the American Society for Bone and Mineral Research; September 2006; Philadelphia, PA. Abstract M341.
29. Fuerst T, Beck TJ, Gaither K, Kothari M, Genant HK. Effect of oral ibandronate on hip structure: results from the BONE study. In: The 28th Annual Meeting of the American Society of Bone and Mineral Research; September 2006; Philadelphia, PA. Abstract SU323.
30. Bare S, Recker S, Recker R, Kimmel D. Influence of alendronate on perisoteal and endocortical bone formation in the ilium of osteoporotic women. Abstract SA414. Presented at the 28th Annual Meeting of the American Society for Bone and Mineral Research; Philadelphia, PA.
31. Eghbali-Fatourechi G., Khosla S., Sanyal A., Boyle W.J., Lacey D.L., and Riggs B.L. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J. Clin. Invest. 111 (2003) 1221-1230
32. Boyle W.J., Simonet W.S., and Lacey D.L. Osteoclast differentiation and activation. Nature 423 (2003) 337-342
33. Meunier P., Roux C., Seeman E., et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. NEJM 350 (2004) 459-468
34. Ma Y.L., Zeng Q., and Donley D. Teriparatide increases bone formation in modeling and remodeling osteons and enhances IGF-II immunoreactivity in postmenopausal women with osteoporosis. J. Bone Miner. Res. 21 (2006) 855-864
35. Jiang Y, Genant H, Zhao J. Effect of strontium ranelate on 3D cortical and trabecular microstructure in postmenopausal osteoporosis in multicenter, double-blind, and placebo controlled studies. In: The 28th Annual Meeting of the American Society of Bone and Mineral Research; September 2006; Philadelphia, PA. Abstract 1160.
36. McClung M.R., Lewiecki E.M., Cohen S.B., et al. Denosumab in postmenopausal women with low bone mineral density. NEJM 8 (2006) 821-831